Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients Single-arm phase II trials may not be appropriate for testing cytostatic ...
The strategy of combining platinum therapy and a PARPi is of significant interest in BRCA-mutated PDAC to enhance tumor response, delay resistance, and improve survival. Herein, we report on a ...